Potential for high clinical, cost burden with MRSA

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.463, 2004-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential for high clinical, cost burden with MRSA

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

MRSA financial burden high, but rapid screening could help

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

C. difficile-associated diarrhoea imposes high cost burden in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 358, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Economic burden of MRSA-related NP substantial

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 668, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Oral linezolid cost saving in MRSA-related infections

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 482, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite